Loading...
Market
Story
ACIP Recommends Lowering Age for Pfizer and Merck Pneumococcal Vaccines to 50
Oct 24, 2024, 12:15 AM
The Advisory Committee on Immunization Practices (ACIP) has recommended lowering the age for pneumococcal vaccination from 65 to 50 years old. This decision aims to expand access and protect more adults from pneumococcal disease, which can cause serious illnesses such as pneumonia, meningitis, and bloodstream infections. The recommendation includes the use of PREVNAR 20®, a 20-valent pneumococcal conjugate vaccine, for adults aged 50 and older. This significant update reflects the committee's efforts to address low vaccine uptake in this age group and improve public health outcomes. The vaccines recommended are made by Pfizer and Merck.
View original story
Similar markets
Pfizer • 25%
GlaxoSmithKline • 25%
Moderna • 25%
Other • 25%
Pfizer leads • 25%
GSK leads • 25%
Moderna leads • 25%
Other leads • 25%
Pfizer has the largest market share • 25%
Moderna has the largest market share • 25%
Novavax has the largest market share • 25%
Other companies have the largest market share • 25%
Pfizer's Abrysvo • 25%
Moderna's RSV vaccine • 25%
GSK's RSV vaccine • 25%
Other • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Capvaxive leads • 33%
Prevnar 20 leads • 33%
Equal market share • 33%
Johnson & Johnson • 25%
AstraZeneca • 25%
Sanofi • 25%
Other • 25%
CVS • 25%
Walgreens • 25%
Rite Aid • 25%
Other • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Under $500 million • 33%
$500 million - $1 billion • 33%
Over $1 billion • 33%